Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Ms14® on Physical Activity of Multiple Sclerosis Patients: A Randomized Triple-Blind Placebo-Controlled Clinical Trial Publisher Pubmed



Rezaeizadeh H1 ; Gharegozli K2 ; Nabavi SM3 ; Shayegannejad V4 ; Ghaffarpoor M5 ; Daneshfard B6, 7 ; Cordato D8, 9 ; Naseri M10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Neurology, Shahid Beheshti University of Medical Science, Tehran, Iran
  3. 3. Center for Neuroscience and Cognition, Royan Institute, Tehran, Iran
  4. 4. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Neurology, Imam Khomeini Hospital, Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Persian Medicine Network (PMN), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  8. 8. Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW, Australia
  9. 9. Department of Neurophysiology, Liverpool Hospital, NSW, Australia
  10. 10. Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran

Source: Multiple Sclerosis and Related Disorders Published:2023


Abstract

Introduction: Multiple Sclerosis (MS) is a neurological disorder with an increasing global prevalence and severe complications. MS14® is a Persian-medicine-derived natural product with herbal and marine origin which has shown beneficial effects in the management of MS complications. In this study, its effect on physical activity of MS patients was investigated. Methods: A triple-blind placebo-controlled clinical trial was conducted. Participants used either MS14 capsule or placebo 3 times a day for 3 weeks. At baseline and end of the study, physical activity indices were assessed using international physical activity questionnaire (IPAQ). Secondary outcome measures were Fatigue Severity Scale (FSS), timed 10 m walk, Ashworth scale, and Timed Get up and Go. Results: A total number of 80 MS patients completed the study. At the end of study, improvement of general physical activity (p-value=0.047) and Timed 10 m walk index (p-value=0.003) in the MS14 group was significant when compared to placebo. No serious adverse effects were observed in this study. Conclusion: Considering the improvement of some physical activity indices, MS14® is seems to be a safe natural product which could be considered as a supplementary treatment in MS patients. Future larger trials are suggested to further evaluate its efficacy. © 2022 Elsevier B.V.
Experts (# of related papers)
Other Related Docs
22. Islamic Fasting and Multiple Sclerosis, BMC Neurology (2014)
37. The Association Between Multiple Sclerosis and Migraine: A Meta-Analysis, Multiple Sclerosis and Related Disorders (2023)
41. Comparing Body Image in Ms Patients and Healthy Individuals, International Journal of Body, Mind and Culture (2020)
43. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)